Please wait while we open this resource.
K
Clinical reviews
CURRENT THERAPEUTIC LANDSCAPE AND FUTURE TREATMENT PERSPECTIVES OF MASH
Suchira Gallage, Olivier Govaere, Quentin M. Anstee, Gerald I. Shulman, Frank Tacke, Mathias Heikenwalder
PDF202616 pages1.8 MB
Metabolic dysfunction-associated steatohepatitis (MASH) is a progressive liver disease that poses risks for cirrhosis and hepatocellular carcinoma, as well as extrahepatic complications. Recent clinical trials have introduced new pharmacological treatments, including THRβ agonists and GLP-1R agonists, which have shown promise for patients with non-cirrhotic MASH. The document emphasizes the heterogeneity of MASH and the importance of tailored treatment strategies that may include lifestyle changes and combinatorial pharmacotherapy.
Sign in to open
Ask this resource
Answers use this document only.
Your first question is free.
More like this
Resources from the same specialty and type. Curated links will replace these when added.
Clinical Resources
Documents that extend or complement this resource.
Hepatitis E Virus, Second Edition (Springer, 2023)
Same clinical topic · Hepatology
AUTOIMMUNE HEPATITIS
Same clinical topic · Hepatology
MOLECULAR MECHANISMS AND PATHOGENESIS OF MASH
Same clinical topic · Hepatology
CIRRHOSIS, PORTAL HYPERTENSION AND HEPATOCELLULAR CARCINOMA: A STAGE-BASED APPROACH
Same clinical topic · Hepatology
NEW APPROACHES TO CHRONIC HEPATITIS B
Same clinical topic · Hepatology
CURRENT THERAPEUTIC LANDSCAPE AND FUTURE TREATMENT PERSPECTIVES OF MASH
Same clinical topic · Hepatology
RANDOMIZED, CONTROLLED CLINICAL TRIAL OF THE DIALIVE LIVER DIALYSIS DEVICE VERSUS STANDARD OF CARE IN PATIENTS WITH ACUTE ON-CHRONIC LIVER FAILURE
Same clinical topic · Hepatology
Intravenous albumin after outpatient paracentesis reduces the risk of AKI hospitalization: A national cohort study
Same clinical topic · Hepatology
LIVER TRANSPLANTATION FOR PATIENTS WITH SEVERE ACUTE ON CHRONIC LIVER FAILURE: IT IS TIME TO CHANGE PARADIGMS
Same clinical topic · Hepatology